80% of the evx-01 vaccine targets trigger a tumor-reactive immune response - evaxion presents striking evx-01 data at the aacr annual meeting

Copenhagen, denmark, april 28, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces new data underscoring the ability of cancer vaccine evx-01 to drive a targeted and robust immune response. designed with evaxion's ai-immunology™ platform, evx-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
EVAX Ratings Summary
EVAX Quant Ranking